- Home
- ZCMD vs PULM Comparison
ZCMD vs PULM Comparison
Compare ZCMD & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- PULM
- Stock Information
- Founded
- ZCMD 2012
- PULM 2003
- Country
- ZCMD China
- PULM United States
- Employees
- ZCMD N/A
- PULM N/A
- Industry
- ZCMD Other Consumer Services
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- ZCMD Real Estate
- PULM Health Care
- Exchange
- ZCMD Nasdaq
- PULM Nasdaq
- Market Cap
- ZCMD 29.0M
- PULM 33.2M
- IPO Year
- ZCMD 2020
- PULM N/A
- Fundamental
- Price
- ZCMD $1.21
- PULM $6.95
- Analyst Decision
- ZCMD
- PULM
- Analyst Count
- ZCMD 0
- PULM 0
- Target Price
- ZCMD N/A
- PULM N/A
- AVG Volume (30 Days)
- ZCMD 626.0K
- PULM 65.8K
- Earning Date
- ZCMD 01-01-0001
- PULM 08-12-2025
- Dividend Yield
- ZCMD N/A
- PULM N/A
- EPS Growth
- ZCMD N/A
- PULM N/A
- EPS
- ZCMD N/A
- PULM N/A
- Revenue
- ZCMD $15,864,773.00
- PULM $1,921,000.00
- Revenue This Year
- ZCMD N/A
- PULM N/A
- Revenue Next Year
- ZCMD N/A
- PULM $134.88
- P/E Ratio
- ZCMD N/A
- PULM N/A
- Revenue Growth
- ZCMD N/A
- PULM N/A
- 52 Week Low
- ZCMD $0.95
- PULM $1.78
- 52 Week High
- ZCMD $2.97
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- ZCMD 50.04
- PULM 42.62
- Support Level
- ZCMD $1.06
- PULM $6.36
- Resistance Level
- ZCMD $1.52
- PULM $7.99
- Average True Range (ATR)
- ZCMD 0.17
- PULM 0.90
- MACD
- ZCMD 0.00
- PULM -0.24
- Stochastic Oscillator
- ZCMD 37.77
- PULM 50.16
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).